OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Subscription and Copyright Information	690
Subscription and Copyright Information	445
Subscription and Copyright Information	277
Subscription and Copyright Information	183
Advisory Board and Contents	174
Structural asymmetry in FGF23 signaling	162
Subscription and Copyright Information	161
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	153
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	146
Muscarinic receptors: from clinic to bench to clinic	139
Shearing of surface mucin saps tumor cell strength	136
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	122
Targeting of Potassium Channels in Cardiac Arrhythmias	111
Direct in vivo CAR T cell engineering	107
Structural pharmacology and mechanisms of GLP-1R signaling	107
Targeting complement in neurodegeneration: challenges, risks, and strategies	101
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	95
Compstatins: the dawn of clinical C3-targeted complement inhibition	94
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	93
Peptides as a therapeutic strategy against Klebsiella pneumoniae	87
Therapeutic inhibition of ferroptosis in neurodegenerative disease	84
Advisory Board and Contents	81
Advisory Board and Contents	81
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	79
Phenotypic approaches for CNS drugs	75

HSV-1 as a gene delivery platform for cancer gene therapy	72
A smart hospital-driven approach to precision pharmacovigilance	72
Ribosome-directed cancer therapies: the tip of the iceberg?	68
Advisory Board and Contents	65
A deep dive into degrader-induced protein-protein interfaces	63
Leveraging human microbiomes for disease prediction and treatment	62
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	60
Emerging strategies for beta cell transplantation to treat diabetes	60
siRNA drug Leqvio (inclisiran) to lower cholesterol	60
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	58
Genetically engineered loaded extracellular vesicles for drug delivery	58
A perspective on psychedelic teratogenicity: the utility of zebrafish models	57
Advisory Board and Contents	57
Engineering ACE2 decoy receptors to combat viral escapability	57
Suzetrigine for moderate to severe acute pain	55
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	55
Subscription and Copyright Information	52
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	52
Close to a year in TIPS’ saddle – I am optimistic	52
Thriving as members of under-represented groups in pharmacology-related careers	51
Lipoxygenases in chronic liver diseases: current insights and future perspectives	50
Could dexmedetomidine be repurposed as a glymphatic enhancer?	49
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	49
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	49
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	48
Mentoring future science leaders to thrive	47
Emerging approaches to induce immune tolerance to therapeutic proteins	46
The structure, function, and pharmacology of MRGPRs	46
Advancing non-destructive analysis of 3D printed medicines	46
The promise of targeted protein degradation approaches	44
Advisory Board and Contents	44
Building unconventional G protein-coupled receptors, one block at a time	43
Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension	42
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	41
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	40
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	39
Fragment-based drug design facilitates selective kinase inhibitor discovery	39
Salt-inducible kinases: new players in pulmonary arterial hypertension?	39
The road less traveled: activating an oncogenic kinase	39
Subscription and Copyright Information	38
A novel function of the M2 muscarinic receptor	38
Promising neuroimmune targets and drugs for CNS diseases	38
Advisory Board and Contents	38
The end of the beginning in understanding SLC22 polyspecificity	36
Targeting intracellular protein–protein interactions with macrocyclic peptides	35
Monkeypox: potential vaccine development strategies	35
Frizzleds act as dynamic pharmacological entities	34
Validation of agent-based models of surface receptor oligomerisation	34
Advisory Board and Contents	33
BTK inhibitors: past, present, and future	33

Decoding pseudouridine: an emerging target for therapeutic development	33
Nanocarriers for oral delivery of biologics: small carriers for big payloads	33
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	31
Metabolic regulation in normal and leukemic stem cells	31
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	31
Recent advances in generative biology for biotherapeutic discovery	31
Development of PROTACs using computational approaches	30
Demographic diversity in platelet function and response to antiplatelet therapy	30
Engineered antibody fusion proteins for targeted disease therapy	29
Circulating tumor cells in precision medicine: challenges and opportunities	28
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	28
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	28
Eflornithine for treatment of high-risk neuroblastoma	28
A novel anticancer pharmacological agent targeting mitochondrial complex I	27
Subscription and Copyright Information	27
Tackling chronic kidney disease in diabetic patients with finerenone	27
GPR35: from enigma to therapeutic target	27
Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology	27
Subscription and Copyright Information	27
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	27
Visceral obesity and HFpEF: targets and therapeutic opportunities	26
Subscription and Copyright Information	26
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	25
Harnessing associative learning paradigms to optimize drug treatment	25
Targeting sensory neuron GPCRs for peripheral neuropathic pain	25
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	24
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	24
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	24
Biologics and cardiac disease: challenges and opportunities	24
Boosting CAR-T cell therapy through vaccine synergy	24
High-power screening (HPS) empowered by DNA-encoded libraries	24
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	24
Neutrophil extracellular traps in wound healing	23
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	23
Taming PRMT5–adaptor protein interactions	23
Subscription and Copyright Information	23
Teaching an old dog new tricks: repurposing β-lactams	23
Recent advancements in vaccine research and development	23
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	23
Challenges and opportunities associated with rare-variant pharmacogenomics	22
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	22
NLRP3 and pyroptosis blockers for treating inflammatory diseases	22
GABAA receptors as targets for treating affective and cognitive symptoms of depression	22
Circadian biology to advance therapeutics for mood disorders	21
Advisory Board and Contents	20
Partial agonists go molecular	20
Potential for targeting small heat shock protein modifications	20
Glymphatic-stagnated edema induced by traumatic brain injury	19
Targeted protein degrader development for cancer: advances, challenges, and opportunities	19
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	19
Membrane protein production and formulation for drug discovery	19
Odorant receptors as potential drug targets	19
GPCR-dependent and -independent arrestin signaling	18
Microfluidic technologies for drug discovery and development: friend or foe?	18
The structure and function of YTHDF epitranscriptomic m6A readers	18
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	18
Advisory Board and Contents	17
Leveraging VGLUT3 Functions to Untangle Brain Dysfunctions	17
Hans Jürg Schatzmann (1924–2021)	17
Bridging the gap in neuropsychiatric translational research	17
Advisory Board and Contents	17